kusabi 300 sc fungicide
ishihara sangyo kaisha, ltd - pyriofenone - suspension concentrate - pyriofenone aryl phenyl ketone active 300.0 g/l - fungicide
ac epoch 125 sc fungicide
axichem pty ltd - epoxiconazole - suspension concentrate - epoxiconazole ungrouped active 125.0 g/l - fungicide
apparent picador 350 sc insecticide
titan ag pty ltd - imidacloprid - suspension concentrate - imidacloprid guanidine active 350.0 g/l - insecticide
kenso agcare avior 250 sc fungicide
kenso corporation (m) sdn. bhd. - azoxystrobin - suspension concentrate - azoxystrobin pyrimidine active 250.0 g/l - fungicide
infinito sc fungicide
bayer cropscience pty ltd - propamocarb hydrochloride; fluopicolide - suspension concentrate - propamocarb hydrochloride carbamate-methylcarbamate active 625.0 g/l; fluopicolide active 62.5 g/l - fungicide
kenso agcare epoxy 125 sc fungicide
kenso corporation (m) sdn. bhd. - epoxiconazole - suspoemulsion - epoxiconazole ungrouped active 125.0 g/l - fungicide
ac promide 500 sc herbicide
axichem pty ltd - propyzamide; stabilizer (monoethylene glycol) - suspension concentrate - propyzamide benzene active 500.0 g/l; stabilizer (monoethylene glycol) ungrouped other 42.0 g/l - herbicide
venom 240 sc insecticide
adama australia pty limited - bifenthrin - suspension concentrate - bifenthrin pyrethroid active 240.0 g/l - miticide
ozcrop 2,4-db 500 sc herbicide
oz crop pty ltd - 2,4-db present as the dimethylamine salt - suspension concentrate - 2,4-db present as the dimethylamine salt phenoxy acids-2,4-db-amine active 500.0 g/l - herbicide
herceptin sc
roche products (nz) ltd - trastuzumab 120 mg/ml - solution for injection - 600 mg/5ml - active: trastuzumab 120 mg/ml excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 trehalose dihydrate water for injection - herceptin sc is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; or b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.